Specifically, our identification of drugs such as PD-0325901, RO-4987655, TAK-733, pimasertib, and RO-5126766, whose effectiveness may be heightened in PCa with elevated SUCLG2 expression, provides a promising foundation for future clinical trials and therapeutic strategies. Here, SUCLG2 is linked to posterior cortical atrophy.